Our mission is to rapidly and unequivocally change the face of medicine
What we stand for
Our values are more than words. They inspire our hiring practice, guide our decision-making and make us who we are.
We maintain intense focus on improving patients’ lives
We explore creative approaches, daring to make well-thought-out decisions and owning the outcomes
We solve complex problems rapidly, with attention and care
Through collaboration and cooperation, we build and maintain a cohesive team that has mutual respect of different viewpoints and talents
We pursue transformative therapies that we believe will make a difference
Led by the pioneers of highly successful kinase inhibitors including Gleevec® (imatinib), our scientific founders launch the company with a vision to revolutionize how kinase medicines are discovered and developed.
Our foundational work focuses on development of a proprietary library of novel compounds that are fully annotated against the human kinome. This library becomes the basis for the company’s successful drug discovery efforts.
We publish foundational preclinical data for the first selective FGFR4 inhibitor for the treatment of patients with FGFR4-activated hepatocellular carcinoma in Cancer Discovery, supporting the advancement of our therapeutic candidate fisogatinib.
Blueprint Medicines launches an initial public offering on the Nasdaq stock exchange.
We initiate clinical development of avapritinib in patients with advanced gastrointestinal stromal tumors and patients with systemic mastocytosis.
We initiate clinical development of fisogatinib in patients with hepatocellular carcinoma.
Blueprint Medicines and Roche enter into a global collaboration to develop up to five novel kinase medicines in the field of cancer immunotherapy.
Clinical proof-of-concept data for avapritinib in patients with advanced gastrointestinal stromal tumors is reported at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.
We initiate clinical development of pralsetinib in patients with RET-altered cancers.
Avapritinib receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA D842V mutation.
Foundational preclinical data and clinical cases for avapritinib in advanced gastrointestinal stromal tumors are published in Science Translational Medicine.
Preliminary Phase 1 clinical data for avapritinib in patients with advanced systemic mastocytosis are selected among more than 6,000 abstracts for presentation during the scientific plenary session at the American Society of Hematology annual meeting.
To support our continued growth and pipeline success, we relocate to new offices in Cambridge, Massachusetts.
Clinical proof-of-concept data for pralsetinib in patients with RET-altered cancers is reported at a clinical trials plenary session at the American Association for Cancer Research annual meeting and published in Cancer Discovery.
Blueprint Medicines and CStone Pharmaceuticals announce strategic collaboration to develop and commercialize avapritinib, fisogatinib and pralsetinib in Mainland China, Hong Kong, Macau and Taiwan.
Avapritinib receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of advanced systemic mastocytosis.
Pralsetinib receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of RET-mutation-positive medullary thyroid cancer that requires systemic treatment and for which there are no acceptable alternative treatments.
Pralsetinib receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of RET-fusion-positive non-small cell lung cancer that has progressed following platinum-based chemotherapy.
We submit a New Drug Application to the U.S. Food and Drug Administration for avapritinib for the treatment of PDGFRA exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST.
Blueprint Medicines and Ipsen announce an exclusive, worldwide license agreement for Clementia Pharmaceuticals, a subsidiary of Ipsen, to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva.
We complete a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for pralsetinib for the treatment of patients with RET fusion-positive non-small cell lung cancer.
We announce approval of AYVAKIT™ (avapritinib) from the U.S. Food and Drug Administration for the treatment of PDGFRA exon 18 mutant GIST including PDGFRA D842V mutations.